KZR•benzinga•
Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate
Summary
Kezar Life Sciences reports positive Phase 2a data for zetomipzomib in autoimmune hepatitis, showing higher response rates and reduced steroid use.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 25, 2025 by benzinga